Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Drugs for Peptic Ulcer Disease: Sucralfate as Mucosal Protective Agents

Drugs for Peptic Ulcer Disease: Sucralfate as Mucosal Protective Agents

In the intricate landscape of the gastric lumen, excessive acid secretion disrupts the natural defense mechanisms, weakening the mucus-bicarbonate barrier. This vulnerability allows pepsin to infiltrate epithelial cells, digesting mucosal proteins and triggering erosion, leading to ulcer formation.
In this scenario, mucosal protective agents like sucralfate play an essential role. Sucralfate, a complex of sulfated sucrose and aluminum hydroxide, demonstrates its usefulness in acidic conditions,...

Drugs for Treatment of Constipation-Predominant IBS

Drugs for Treatment of Constipation-Predominant IBS

Pharmacological therapies for IBS-C are designed to alleviate abdominal discomfort and enhance bowel function. In patients with IBS-C, fiber supplements may help soften stools and decrease straining, but may also lead to increased gas production and bloating. Osmotic laxatives like milk of magnesia are frequently used to soften stools and increase stool frequency in IBS-C patients. In addition, two drugs approved for use in severe IBS-C adult cases are linaclotide (Linzess) and lubiprostone...

Drugs for Treatment of Ulcerative Colitis in IBD

Drugs for Treatment of Ulcerative Colitis in IBD

Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide generation.

Assessment of the Gastrointestinal System I: Subjective Data

Assessment of the Gastrointestinal System I: Subjective Data

Assessing the gastrointestinal (GI) system is a complex process that begins with collecting subjective data. This data, collected through patient interviews, provides crucial insights into the patient's health history, perception patterns, and lifestyle habits, all contributing significantly to GI health.
Health History
The initial step in assessing the GI system is obtaining a comprehensive health history. This includes inquiring about the patient's history or presence of problems related to...

Inflammatory Bowel Disease I: Ulcerative Colitis

Inflammatory Bowel Disease I: Ulcerative Colitis

Introduction
Inflammatory bowel disease, or IBD, encompasses a group of disorders characterized by chronic inflammation or ulceration of the gastrointestinal tract.
Risk Factors
The exact cause of IBD remains unclear, although it is believed to be due to a mix of genetic, environmental, microbial, and immune factors. Genetic factors are significant in determining susceptibility to IBD, with family history being a critical risk factor. Individuals with a first-degree relative who has IBD are at...

Drug toxicity: Drug–Drug Interaction

Drug toxicity: Drug–Drug Interaction

Drug–drug interactions can precipitate toxicity through multiple mechanisms. Absorption interactions alter how drugs enter the body, exemplified when ranitidine increases the absorption of basic drugs, while cholestyramine decreases the levels of propranolol. Protein binding interactions occur when drugs share the same binding sites on plasma proteins. Drugs like aspirin and warfarin, when bound in excess, can lead to increased free drug concentrations, enhancing the potential for...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Persistence with non-selective NSAIDs and celecoxib among patients with gastroesophageal reflux disease and osteoarthritis or rheumatoid arthritis.

Current medical research and opinion·2010

Same author

Risk factors for NSAID-associated upper GI clinical events in a long-term prospective study of 34 701 arthritis patients.

Alimentary pharmacology & therapeutics·2010

Same author

Nonsteroidal anti-inflammatory drug gastrointestinal toxicity.

Current opinion in gastroenterology·2006

Same author

Nonsteroidal anti-inflammatory drug gastrointestinal toxicity.

Current opinion in gastroenterology·2006

Same author

Three-year oral pantoprazole administration is effective for patients with Zollinger-Ellison syndrome and other hypersecretory conditions.

Alimentary pharmacology & therapeutics·2006

Same author

Upper gastrointestinal tolerability of once weekly alendronate 70 mg with concomitant non-steroidal anti-inflammatory drug use.

Alimentary pharmacology & therapeutics·2005

Search research articles

Related Experiment Video

Updated: Jul 16, 2026

Investigating Intestinal Inflammation in DSS-induced Model of IBD

Investigating Intestinal Inflammation in DSS-induced Model of IBD

Published on: February 1, 2012

NSAID gastrointestinal toxicity.

¹Medical Service, Department of Veterans Affairs Medical Center and Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, Texas 75216, USA. bcryer@mednet.swmed.edu

Current Opinion in Gastroenterology

|October 13, 2006

Summary

Nonsteroidal anti-inflammatory drugs (NSAIDs) commonly cause gastrointestinal ulcers. Recent research has advanced understanding of NSAID toxicity, identified at-risk patients, and developed safer NSAID alternatives.

More Related Videos

Analyzing Beneficial Effects of Nutritional Supplements on Intestinal Epithelial Barrier Functions During Experimental Colitis

Analyzing Beneficial Effects of Nutritional Supplements on Intestinal Epithelial Barrier Functions During Experimental Colitis

Published on: January 5, 2017

Synthesis of a Borylated Ibuprofen Derivative Through Suzuki Cross-Coupling and Alkene Boracarboxylation Reactions

Synthesis of a Borylated Ibuprofen Derivative Through Suzuki Cross-Coupling and Alkene Boracarboxylation Reactions

Published on: November 30, 2022

Related Experiment Videos

Last Updated: Jul 16, 2026

Investigating Intestinal Inflammation in DSS-induced Model of IBD

Investigating Intestinal Inflammation in DSS-induced Model of IBD

Published on: February 1, 2012

Analyzing Beneficial Effects of Nutritional Supplements on Intestinal Epithelial Barrier Functions During Experimental Colitis

Analyzing Beneficial Effects of Nutritional Supplements on Intestinal Epithelial Barrier Functions During Experimental Colitis

Published on: January 5, 2017

Synthesis of a Borylated Ibuprofen Derivative Through Suzuki Cross-Coupling and Alkene Boracarboxylation Reactions

Synthesis of a Borylated Ibuprofen Derivative Through Suzuki Cross-Coupling and Alkene Boracarboxylation Reactions

Published on: November 30, 2022

Area of Science:

Gastroenterology
Pharmacology
Internal Medicine

Background:

Nonsteroidal anti-inflammatory drugs (NSAIDs) are widely used for pain and inflammation.
Upper gastrointestinal ulcers are the most common adverse effects of NSAID use.
NSAID-induced gastrointestinal toxicity remains a significant clinical challenge.

Purpose of the Study:

To review recent advances in understanding and mitigating NSAID-induced gastrointestinal toxicity.
To highlight new developments in NSAID safety and risk management.
To provide an overview of improved NSAID safety profiles.

Main Methods:

Literature review of recent laboratory and clinical studies.
Analysis of advancements in NSAID gastrointestinal safety.
Synthesis of findings on NSAID toxicity mechanisms and risk factors.

Main Results:

Delineation of mechanisms underlying NSAID-induced gastrointestinal toxicity.
Identification of patient populations at higher risk for NSAID complications.
Development of NSAID classes with improved gastrointestinal safety profiles.
Recognition of co-therapies that can reduce NSAID toxicity.

Conclusions:

Significant progress has been made in reducing NSAID gastrointestinal toxicity.
Recent research has enhanced the understanding of NSAID-related risks.
Newer NSAID formulations and therapeutic strategies offer improved gastrointestinal safety.